0001691082-24-000001.txt : 20240110 0001691082-24-000001.hdr.sgml : 20240110 20240110151306 ACCESSION NUMBER: 0001691082-24-000001 CONFORMED SUBMISSION TYPE: D/A PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20240110 DATE AS OF CHANGE: 20240110 EFFECTIVENESS DATE: 20240110 FILER: COMPANY DATA: COMPANY CONFORMED NAME: LB PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001691082 ORGANIZATION NAME: IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D/A SEC ACT: 1933 Act SEC FILE NUMBER: 021-492682 FILM NUMBER: 24526340 BUSINESS ADDRESS: STREET 1: 575 MADISON AVENUE CITY: NEW YORK STATE: NY ZIP: 10022 BUSINESS PHONE: 917-450-6581 MAIL ADDRESS: STREET 1: 575 MADISON AVENUE CITY: NEW YORK STATE: NY ZIP: 10022 FORMER COMPANY: FORMER CONFORMED NAME: LB PHARMACEUTICALS INC. DATE OF NAME CHANGE: 20161129 D/A 1 primary_doc.xml X0708 D/A LIVE 0001691082 LB PHARMACEUTICALS INC 575 MADISON AVENUE NEW YORK NY NEW YORK 10022 212-605-0230 DELAWARE LB PHARMACEUTICALS INC. Corporation true Zachary Prensky 575 Madison Avenue New York NY NEW YORK 10022 Executive Officer Director Robert Ruffolo 575 Madison Avenue New York NY NEW YORK 10022 Director Rebecca Luse 575 Madison Avenue New York NY NEW YORK 10022 Director Rajul Jain 575 Madison Avenue New York NY NEW YORK 10022 Director Ran Nussbaum 575 Madison Avenue New York NY NEW YORK 10022 Director Chen Yu 575 Madison Avenue New York NY NEW YORK 10022 Director Marc Panoff 575 Madison Avenue New York NY NEW YORK 10022 Executive Officer Anna Eramo 575 Madison Avenue New York NY NEW YORK 10022 Executive Officer Andrew Vaino 575 Madison Avenue New York NY NEW YORK 10022 Executive Officer Pharmaceuticals Decline to Disclose 06b true 0001691082-23-000004 2023-08-29 false true true false 0 Maxim Group LLC 120708 None None 300 Park Avenue 16th Floor New York NY NEW YORK 10022 All States true Agile Capital Markets None Agile Capital Markets None 33 rue Lafayette Paris I0 FRANCE 75009 true 110730354 110730354 0 The total offering amount of $110,730,354 consists of $75,000,000 new cash offering and $35,730,354 automatic conversion of existing convertible notes, for which notes (including underlying securities) a Form D was previously filed upon the original sale. false 6 2465000 735000 1333000 false LB PHARMACEUTICALS INC Zachary Prensky Zachary Prensky Chief Executive Officer 2024-01-10